
Sign up to save your podcasts
Or
In part one of this three-part series, Dr. Justin Abbatemarco and Dr. Jiwon Oh discuss how Bruton Tyrosine Kinase (BTK) Inhibitors work and how they vary from other disease-modifying therapies.
Show reference:
https://www.nejm.org/doi/full/10.1056/NEJMoa2415985
https://www.nejm.org/doi/full/10.1056/NEJMoa2415988
4.8
129129 ratings
In part one of this three-part series, Dr. Justin Abbatemarco and Dr. Jiwon Oh discuss how Bruton Tyrosine Kinase (BTK) Inhibitors work and how they vary from other disease-modifying therapies.
Show reference:
https://www.nejm.org/doi/full/10.1056/NEJMoa2415985
https://www.nejm.org/doi/full/10.1056/NEJMoa2415988
287 Listeners
48 Listeners
498 Listeners
280 Listeners
3,326 Listeners
255 Listeners
12 Listeners
22 Listeners
195 Listeners
517 Listeners
349 Listeners
6,218 Listeners
183 Listeners
366 Listeners
79 Listeners